Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
|4||Active, not recruiting||
The Oncopanel Pilot (TOP) Study
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
† Study has passed its completion date and status has not been verified in more than two years.